Clinical Trial Results:
An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.
Summary
|
|
EudraCT number |
2017-004043-21 |
Trial protocol |
FR |
Global end of trial date |
24 Jun 2021
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Jul 2022
|
First version publication date |
14 Jul 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
16-OBE2109-016
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
ObsEva SA
|
||
Sponsor organisation address |
12, Chemin des Aulx, Geneva, Switzerland,
|
||
Public contact |
Clinical Trials Information, ObsEva SA, +41 (0)225523840, clinicaltrials@obseva.ch
|
||
Scientific contact |
Clinical Trials Information, ObsEva SA, +41 (0)225523840, clinicaltrials@obseva.ch
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 Nov 2021
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
24 Jun 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
24 Jun 2021
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the efficacy of 200 mg linzagolix (OBE2109) daily for 12 weeks followed by 100 mg linzagolix daily for 12 weeks on reduction of the volume of rectovaginal endometriosis node. In addition, the overall safety of 24 weeks of daily administration of linzagolix in patients with rectovaginal endometriosis was assessed.
|
||
Protection of trial subjects |
The study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and with Good Clinical Practice (GCP) rules and in line with local regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Oct 2019
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
3 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
France: 3
|
||
Worldwide total number of subjects |
3
|
||
EEA total number of subjects |
3
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
3
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
The study was conducted at one clinical site in France. | ||||||
Pre-assignment
|
|||||||
Screening details |
A total of 3 patients were screened and enrolled in the study. Nine subjects were planned to be included, but due to difficulties in recruitment, recruitment was stopped. | ||||||
Period 1
|
|||||||
Period 1 title |
Baseline
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Baseline | ||||||
Arm description |
Patients received linzagolix 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
linzagolix
|
||||||
Investigational medicinal product code |
OBE2109
|
||||||
Other name |
|||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Once daily oral administration of linzagolix 200 mg for 12 weeks followed by 100 mg for 12 weeks.
|
||||||
|
|||||||
Period 2
|
|||||||
Period 2 title |
Week 24
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Week 24 | ||||||
Arm description |
Patients received linzagolix 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
linzagolix
|
||||||
Investigational medicinal product code |
OBE2109
|
||||||
Other name |
|||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Once daily oral administration of linzagolix 200 mg for 12 weeks followed by 100 mg for 12 weeks.
|
||||||
|
|||||||
Period 3
|
|||||||
Period 3 title |
Follow-up
|
||||||
Is this the baseline period? |
No | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Follow-up | ||||||
Arm description |
At week 24, the patients entered a 12-week follow-up period without any active treatment. | ||||||
Arm type |
No intervention | ||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline
|
||
Reporting group description |
Patients received linzagolix 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks. | ||
Reporting group title |
Week 24
|
||
Reporting group description |
Patients received linzagolix 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks. | ||
Reporting group title |
Follow-up
|
||
Reporting group description |
At week 24, the patients entered a 12-week follow-up period without any active treatment. |
|
|||||||||
End point title |
Changes from baseline to Week 24 in volume of rectovaginal nodes measured by MRI measuring central lesion and the entire invasion front, i.e. including the specula. [1] | ||||||||
End point description |
|||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Week 24
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The statistical analyses described in the protocol were not performed due to the low number of participants. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse event (AE) data were collected continuously during the study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
AE data were obtained at scheduled study visits based on physical examination, vital signs and biological laboratory assessments. In addition, the patients reported AEs spontaneously and/or through questioning. Only treatment emergent AEs (TEAEs) are reported here.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Enrolled analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
The enrolled analysis set (EAS) is defined for this study as all enrolled patients. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
20 Aug 2018 |
• Addition of ECG monitoring
• Clarification of the fasting requirements
• Change of urine pregnancy test to serum pregnancy test
• Add possibility to perform Screening, Week 12, 24 and 36 visits over 2 days
• More accurate wording about IMP administration and packaging
• Change in the visit window at the Week 12 and 24 visits
• Added wording in case the result of the endometrium biopsy of Day 1 is not available |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
Only 3 participants were enrolled, whereas 9 were initially planned and judged suitable for an exploratory assessment of linzagolix in patients with rectovaginal endometriosis, so that the results of this study must be interpreted with caution. |